All News

acr_session2.jpeg

Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology

d Kathryn H. Dao, M.D.

Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.

Read Article
PSA2L.jpg

How early is early in psoriatic arthritis?

d Antoni Chan, MD, PhD

Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment.

Read Article
syringe

IV Secukinumab for AxSpa

d Eric Dein, MD

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 inhibitors: The new hype in SLE and LN management?

d Sheila Reyes, MD

Inhibitors of SGLT2 have been shown to reduce MACE in patients with type 2 DM and established cardiovascular disease. In patients with chronic kidney disease at risk of progression, SGLT2 inhibitors have shown reduction in risk of eGFR decline and hospitalization. In SLE, clinical trials have yet to explore the possible role of SGLT2i in improving renal outcomes in lupus nephritis. A couple of abstracts presented during the meeting tackled the topic of SGLT2 inhibition in SLE. 

Read Article
Stills,continuum

New Biomarkers and Therapeutics Show Potential in Still's Disease

d Bella Mehta, MBBS, MS

Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis (sJIA) characterized by sustained fever, salmon-colored rash, and arthritis.

Read Article
Excellent pragmatic RCT, TNF withdrawal in RA Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4 Supports my practice of generally continuing TNFs long term Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue @RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z
Mike Putman EBRheum ( View Tweet)
Vaccination appears to be effective and safe post CAR-T treatment. This sets the stage for better understanding of the patient experience. Dr. Schett #ACR23 @RheumNow https://t.co/OQCNTt5wPh
Dr. Rachel Tate  ( View Tweet)
In case you missed it! Watch our ACR Monday Recap of the meeting with me, @RheumNow @EBRheum and @ericdeinmd. #ACR23 @uptoTate https://t.co/GpMdev0Yk7

TheDaoIndex KDAO2011 ( View Tweet)

#ACR23 Abs #2548 showed incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomized to BKZ 160 mg Q4W vs PBO. https://t.co/kBLQnJbTU2 @rheumnow https://t.co/regYgvvCts
Dr. Rachel Tate  ( View Tweet)
Bimekizumab is Coming… in 3rd Place Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis. https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR23 Daily Recap - MONDAY Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/0WXuV3wzzF
Dr. John Cush RheumNow ( View Tweet)
ACR2023 Daily Recap - MONDAY Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/qOjSd8vuB3
Dr. John Cush RheumNow ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/jjcnekqVPe
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Early experience w/SGLT2i in SLE (Prof Petri): 👉Reduction of decline in eGFR after SGLT2i 👉Improvement in RUPCR after SGLT2i BUT observed differences not significant when compared w/prior to starting SGLT2i Small sample size. Longer ffup needed. #ACR23 ABST1490 @RheumNow https://t.co/IhVFacRi0g
sheila  ( View Tweet)
Went into more depth on this great topic of IBD in SpA on @RheumNow #ACR23 Should we be screening SpA patients with fecal calprotectin to look for undiagnosed SpA? https://t.co/TmXhm2MEfO https://t.co/SWJSqF5pkW

Eric Dein  ( View Tweet)

You said that CAR-T needs a #RCT in severe #SLE ⁦@RheumNow⁩ ⁦@ACRheum⁩ #ACR23 https://t.co/yilohqz1YE
Janet Pope  ( View Tweet)
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Janet Pope  ( View Tweet)
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope  ( View Tweet)
#ACR23 highlights from PlenaryII 🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it. 🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP #ACR23 @RheumNow @ACRheum #ACRbest

Janet Pope  ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×